Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,060.30
-18.60 (-0.89%)
At close: Feb 13, 2026
Mankind Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 19,910 | 19,129 | 12,819 | 14,335 | 12,654 |
Depreciation & Amortization | 5,940 | 3,697 | 3,208 | 1,616 | 1,154 |
Other Amortization | 272.2 | 87.3 | 51.07 | 49.83 | 35.27 |
Loss (Gain) From Sale of Assets | -1,614 | -4.8 | -16.65 | 37.41 | 30.45 |
Asset Writedown & Restructuring Costs | 43.5 | 131.6 | 135.6 | -22.37 | 38.88 |
Loss (Gain) From Sale of Investments | -1,608 | -1,335 | -374.31 | -1,049 | -451.54 |
Loss (Gain) on Equity Investments | -122.4 | -152.1 | -124.24 | -144.48 | -116.77 |
Stock-Based Compensation | 266.4 | 231.9 | 0.59 | - | - |
Provision & Write-off of Bad Debts | 136.1 | 139.1 | 137.89 | 115.43 | 7.54 |
Other Operating Activities | 2,290 | -435.9 | 609.71 | 91.25 | -1,049 |
Change in Accounts Receivable | -1,236 | -2,899 | -2,053 | -659.53 | 2,002 |
Change in Inventory | -2,207 | -550 | 2,618 | -5,767 | -2,844 |
Change in Accounts Payable | -1,460 | 974.6 | -650.19 | 4,198 | -781.51 |
Change in Other Net Operating Assets | 3,439 | 2,299 | 1,753 | -3,633 | 676.93 |
Operating Cash Flow | 24,134 | 21,524 | 18,133 | 9,198 | 11,372 |
Operating Cash Flow Growth | 12.12% | 18.70% | 97.15% | -19.12% | 6.07% |
Capital Expenditures | -4,608 | -3,153 | -7,890 | -4,649 | -3,054 |
Sale of Property, Plant & Equipment | 119.8 | 75.1 | 60.48 | 31.46 | 7.43 |
Cash Acquisitions | -137,027 | - | -38.27 | - | - |
Divestitures | 5,625 | - | - | - | - |
Sale (Purchase) of Intangibles | -593.2 | -670 | -430.49 | -18,807 | -69.05 |
Sale (Purchase) of Real Estate | 79.9 | - | - | - | - |
Investment in Securities | 9,013 | -17,388 | -2,366 | 9,430 | -9,478 |
Other Investing Activities | 467.7 | 319.4 | 123.57 | 302.84 | 374.47 |
Investing Cash Flow | -126,924 | -20,817 | -10,541 | -13,691 | -12,222 |
Short-Term Debt Issued | 65,622 | 3,746 | 10,947 | 12,723 | 1,268 |
Long-Term Debt Issued | 58,891 | 260.9 | 38.45 | 58.6 | 4,522 |
Total Debt Issued | 124,513 | 4,007 | 10,986 | 12,782 | 5,789 |
Short-Term Debt Repaid | -44,799 | -3,398 | -17,642 | -6,454 | -176.98 |
Long-Term Debt Repaid | -6,039 | -294.5 | -322.25 | -104.29 | -4,519 |
Total Debt Repaid | -50,838 | -3,693 | -17,964 | -6,558 | -4,696 |
Net Debt Issued (Repaid) | 73,675 | 314.4 | -6,978 | 6,224 | 1,094 |
Issuance of Common Stock | 29,632 | - | - | - | - |
Other Financing Activities | -981.3 | -261.7 | -419.31 | -177.86 | -1,172 |
Financing Cash Flow | 102,326 | 52.7 | -7,397 | 6,046 | -78.11 |
Foreign Exchange Rate Adjustments | 13.1 | 11.7 | 23.15 | 4.78 | 3.75 |
Miscellaneous Cash Flow Adjustments | 669.7 | - | - | - | - |
Net Cash Flow | 218.7 | 771.9 | 217.6 | 1,557 | -924.03 |
Free Cash Flow | 19,526 | 18,371 | 10,243 | 4,549 | 8,318 |
Free Cash Flow Growth | 6.29% | 79.36% | 125.16% | -45.31% | -1.47% |
Free Cash Flow Margin | 16.00% | 17.90% | 11.71% | 5.85% | 13.38% |
Free Cash Flow Per Share | 48.25 | 45.79 | 25.57 | 11.36 | 20.77 |
Cash Interest Paid | 981.3 | 261.7 | 419.31 | 177.86 | 171 |
Cash Income Tax Paid | 5,668 | 4,415 | 3,231 | 4,995 | 4,541 |
Levered Free Cash Flow | 7,650 | 12,640 | 7,117 | -16,379 | 5,813 |
Unlevered Free Cash Flow | 10,280 | 12,814 | 7,369 | -16,031 | 5,934 |
Change in Working Capital | -1,464 | -175.7 | 1,667 | -5,861 | -946.32 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.